pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

4,879 catalysts · 4,876 phase readout · 2,332 8k filing · 286 earnings · 274 pdufa · 129 phase 2 completion · 61 phase 1 completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 0 catalysts2026-10-20: 1 catalyst2026-10-21: 0 catalysts2026-10-22: 1 catalyst2026-10-23: 0 catalysts2026-10-24: 0 catalysts2026-10-25: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type: drug expiry×type: phase readout×clear all
type
  • phase readout4,876
  • 8k filing2,332
  • earnings286
  • pdufa274
  • phase 2 completion129
  • phase 1 completion61
phase 1 initiation
32
  • phase 1 2 completion28
  • phase 0 trial completion22
  • phase 2 initiation16
  • therapy area
    • Infectious Disease3

    Date TBD

    50
    ›RECRUITINGphase readoutNCT06785636: Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617

    Sponsor: Pathos AI, Inc.. Phase: PHASE1. Conditions: mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Neoplasms, Male, Urogenital Neoplasms, Urogenital Cancers, Prostatic Diseases, Prostatic Neoplasms, Male Urogenital Diseases, Neoplasms, Neoplasms by Site, Prostate Cancer

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06170736: Radiofrequency Ablation vs Doppler-guided Haemorrhoidal Artery Ligation in the Treatment of Haemorrhoidal Disease

    Sponsor: Centre Hospitalier Departemental Vendee. Phase: NA. Conditions: Haemorrhoids, Internal Haemorrhoids, Grade II/III Haemorrhoids

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06057181: Helix Research Network

    Sponsor: Helix, Inc. Phase: . Conditions: Genetic Predisposition to Disease, Genetics Disease

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT06485219: A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

    Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd. Phase: PHASE2. Conditions: Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL)

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07334028: Study to Find Out the Timing for the Optimal Imaging of Varicose Veins Using Infrared Thermography.

    Sponsor: The Whiteley Clinic. Phase: . Conditions: Varicose Veins Leg

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06980428: A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia

    Sponsor: AstraZeneca. Phase: PHASE1. Conditions: Healthy Participants, Dyslipidemia

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06088628: Micro-expressions in Patients With Prolonged Disorders of Consciousness

    Sponsor: First Affiliated Hospital of Zhejiang University. Phase: . Conditions: Consciousness Disorders

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07445867: Effectiveness Evaluation of a Comprehensive School Readiness Summer Program for Young Children At-Risk

    Sponsor: Florida International University. Phase: NA. Conditions: Externalizing Behavior

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT05584800: Study of ZGGS18 in Patients With Advanced Solid Tumors

    Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Phase: PHASE1. Conditions: Advanced Solid Tumor

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06464107: Endometrial Cell Collection With the PadKit

    Sponsor: Hackensack Meridian Health. Phase: NA. Conditions: Neoplasms

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07533136: Tafenoquine Combinations for Improved Radical Cure Efficacy of Plasmodium Vivax

    Sponsor: Walter Reed Army Institute of Research (WRAIR). Phase: NA. Conditions: Uncomplicated P. Vivax Mono-infection

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT06638671: Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity

    Sponsor: University of Virginia. Phase: PHASE4. Conditions: Exercise Capacity, Metformin

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT05748171: A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

    Sponsor: Pfizer. Phase: PHASE2. Conditions: ACUTE LYMPHOBLASTIC LEUKEMIA

    full page →ctgov ↗
    ›ENROLLING_BY_INVITATIONphase readoutNCT06513871: Evaluating Social Perception Dynamics

    Sponsor: Yale University. Phase: NA. Conditions: Mental Health Issue, COVID-19

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06496971: A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients

    Sponsor: NaviFUS Corporation. Phase: PHASE3. Conditions: Glioblastoma Multiforme, Glioblastoma, Glioblastoma Multiforme, Adult, Glioma, Brain Tumor, Brain Tumor, Recurrent, Neoplasms, Neoplasms, Nerve Tissue

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07317544: Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Healthy Adults With and Without Androgenetic Alopecia

    Sponsor: Absci Pty Ltd.. Phase: PHASE1. Conditions: Androgenetic Alopecia (AGA), Healthy Volunteers - Male and Female

    full page →ctgov ↗
    ›WITHDRAWNphase readoutNCT07474844: Structured TXI-RDI Integration for Endoscopic Resection

    Sponsor: Medical College of Wisconsin. Phase: NA. Conditions: Polyp Colorectal, Endoscopic Mucosal Resection

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT03904134: Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)

    Sponsor: Center for International Blood and Marrow Transplant Research. Phase: NA. Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Non-hodgkin Lymphoma, Hodgkin Lymphoma, Acquired Aplastic Anemia, Sickle Cell Disease

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07137481: Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies

    Sponsor: M.D. Anderson Cancer Center. Phase: PHASE2. Conditions: Hematological Malignancies

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07280481: Weekly Dynamics of Psychopathological and Symptom Networks During Mindfulness-Based Interventions for Emotional Distress

    Sponsor: Peking University. Phase: NA. Conditions: Depression, Anxiety, Emotional Disorders

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07317219: Ayahuasca, Esketamine and Body Image Perception

    Sponsor: University of Sao Paulo. Phase: NA. Conditions: Healthy Women Volunteers

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06188065: Eosinopenia in Severe COPD Exacerbation

    Sponsor: Northumbria Healthcare NHS Foundation Trust. Phase: . Conditions: Chronic Obstructive Pulmonary Disease

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT06225167: Pharmacist-Driven Stress Ulcer Prophylaxis Minimization in the Intensive Care Unit

    Sponsor: Methodist Health System. Phase: . Conditions: Stress Ulcer

    full page →ctgov ↗
    ›WITHDRAWNphase readoutNCT01634867: Rapid Sequence Intubation Drug Delivery Using Intraosseous and IV Access in Pediatric Patients Observational Study

    Sponsor: Vidacare Corporation. Phase: . Conditions: Airway Control

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06361407: Sensory and Cognitive Predictions, and Their Disruptions in Schizophrenia

    Sponsor: Centre Psychothérapique de Nancy. Phase: NA. Conditions: Schizophrenia, Sensory Processing Disorder

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT01625000: Safety and Efficacy of MP-214 in Patients With Schizophrenia

    Sponsor: Tanabe Pharma Corporation. Phase: PHASE2. Conditions: Schizophrenia

    full page →ctgov ↗
    ›SUSPENDEDphase readoutNCT05478707: Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes

    Sponsor: University of Virginia. Phase: PHASE2. Conditions: Diabetes Mellitus, Type 1, Endothelial Dysfunction

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07437807: Vision Therapy Outcomes in Amblyopia: Linking Brain Plasticity With Visual Perceptual Skills

    Sponsor: Okan University. Phase: . Conditions: Amblyopia

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT04940936: Shared Decision Making on Radiation Dose for Lung Malignancies

    Sponsor: Vejle Hospital. Phase: NA. Conditions: Decision Making, Shared, Stereotactic Body Radiation Therapy, Lung Cancer, Non-small Cell, Radiation Toxicity, Lung Metastases

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07248111: Effectiveness of the Mindful Compassion Care Program for Healthcare Professionals in Oncology and Palliative Care

    Sponsor: Azienda USL Reggio Emilia - IRCCS. Phase: NA. Conditions: Professional Quality of Life, Palliative Care, Oncology

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06209411: Community Health Worker-Led Postpartum Diabetes Screening

    Sponsor: Weill Medical College of Cornell University. Phase: NA. Conditions: Diabetes Mellitus, Type 2, Gestational Diabetes

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07153471: A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

    Sponsor: Eli Lilly and Company. Phase: PHASE3. Conditions: Osteoarthritis

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT01616875: Bristol Bladder Trial

    Sponsor: University Hospitals Bristol and Weston NHS Foundation Trust. Phase: PHASE2. Conditions: Infiltrating Bladder Urothelial Carcinoma

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07217301: IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed

    Sponsor: Fortvita Biologics (USA)Inc.. Phase: PHASE3. Conditions: iO Resistant sqNSCLC

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07480681: Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor

    Sponsor: Shanghai Henlius Biotech. Phase: PHASE1. Conditions: Advanced/Metastatic Solid Tumors

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07502365: BIG Chicago: A Trial of Basic Income Guarantee for Young People Living With HIV

    Sponsor: University of Chicago. Phase: NA. Conditions: HIV, Financial Stress

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT04958265: A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

    Sponsor: Hoffmann-La Roche. Phase: PHASE3. Conditions: Atypical Hemolytic Uremic Syndrome

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT05234567: A Prospective Sub-Study of the Global Hypophosphatasia Registry

    Sponsor: Alexion Pharmaceuticals, Inc.. Phase: . Conditions: Hypophosphatasia

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT03634267: MRI-Guided Brachytherapy in Treating Participants With HPV-Associated Stage IB2-IVA Cervical or Stage II-IVA Vaginal Cancer

    Sponsor: M.D. Anderson Cancer Center. Phase: PHASE1. Conditions: Human Papillomavirus-Related Carcinoma, Human Papillomavirus-Related Cervical Carcinoma, Stage IB2 Cervical Cancer AJCC v8, Stage II Cervical Cancer AJCC v8, Stage II Vaginal Cancer AJCC v8, Stage IIA Cervical Cancer AJCC v8, Stage IIA Vaginal Cancer AJCC v8, Stage IIA1 Cervical Cancer AJCC v8, Stage IIA2 Cervical Cancer AJCC v8, Stage IIB Cervical Cancer AJCC v8, Stage IIB Vaginal Cancer AJCC v8, Stage III Cervical Cancer AJCC v8, Stage III Vaginal Cancer AJCC v8, Stage IIIA Cervical Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Vaginal Cancer AJCC v8

    full page →ctgov ↗
    ›ENROLLING_BY_INVITATIONphase readoutNCT07566936: Digital vs Conventional Stabilizing Splints in Temporomandibular Disorders

    Sponsor: Shifa Tameer-e-Millat University. Phase: NA. Conditions: Temporomandibular Disorders (TMD)

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07428811: Effects of Task-Based Mirror Therapy for Post-stroke Shoulder-Hand Syndrome

    Sponsor: Riphah International University. Phase: NA. Conditions: Stroke

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07328711: Immunomodulatory Therapy and Predictors of Clinical Cure in Chronic Hepatitis B

    Sponsor: Peking University People's Hospital. Phase: EARLY_PHASE1. Conditions: Chronic Hepaititis B

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07370571: NO AXILLARY SURGERY IN EARLY BREAST CANCER (OXIGENATE)

    Sponsor: Clinica Universidad de Navarra, Universidad de Navarra. Phase: . Conditions: Breast Cancer

    full page →ctgov ↗
    ›TERMINATEDphase readoutNCT04948671: Primary Hyperparathyroidism and Gut Microbiota

    Sponsor: Centre Hospitalier Universitaire Vaudois. Phase: . Conditions: Hyperparathyroidism, Primary

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07473128: Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer

    Sponsor: Pharmacosmos A/S. Phase: PHASE3. Conditions: Limited Stage Small Cell Lung Cancer

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT02297165: Efficacy Study of an Olfactory Stimulation Program for the Recuperation of Autobiographical Memories in Anorexia

    Sponsor: Lille Catholic University. Phase: NA. Conditions: Anorexic

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06721065: A Study of Language Interpretation Solutions for People With Breast Cancer

    Sponsor: Memorial Sloan Kettering Cancer Center. Phase: NA. Conditions: Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT05456867: A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia

    Sponsor: AstraZeneca. Phase: . Conditions: NSCLC, Non-small-cell Lung Carcinoma

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT05050500: Effects of Dapagliflozin on Inflammatory Factorslevel and Prognosis in Type 2 Diabetes With Acute Myocardial Infarction

    Sponsor: Qingdao Central Hospital. Phase: PHASE4. Conditions: Myocardial Infarction, Diabete Type 2, Glucose Intolerance

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07134400: Prevalence and Functional Impact of Urinary Incontinence in Women With Chronic Obstructive Pulmonary Disease Undergoing Rehabilitation: a Cross-sectional Study

    Sponsor: Fondation Hôpital Saint-Joseph. Phase: . Conditions: COPD (Chronic Obstructive Pulmonary Disease), Urinary Incontinence (UI), Pulmonary Rehabilitation

    full page →ctgov ↗
    ← prev
    page 23 of 98
    next →